Is NAD+ IV Therapy Safe? Risks and a Clinic Checklist

NAD+ IV therapy has meaningful uncertainties and risks, even when sold as a wellness service. You need to consider the infusion itself, the preparation's quality and whether its uncertain benefit justifies an invasive procedure. A small study cannot establish a reliable rate of rare or long-term harm.

For a new racing or irregular-heartbeat sensation, read the palpitations and urgent-symptom guide. Significant chest symptoms, breathlessness or fainting should not be dismissed as an expected infusion sensation.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Willow

NAD+ injection alongside a compounded GLP-1 line

See Willow↗

A polished clinic and a reassuring intake form are useful service features, but neither supplies the missing safety evidence. Before paying for a series, get specific answers about the people, product and plan.

What symptoms have been reported during infusion?

A 2026 retrospective pilot reported gastrointestinal symptoms and chest pressure during NAD+ infusions. It involved only 14 clients across NAD+ and NR groups and had commercial funding and author ties ¹. That design offers observations, not a comprehensive safety estimate.

Do not dismiss new chest symptoms as a normal sign of an infusion “working.” Tell the treating clinician immediately. Severe symptoms require urgent assessment. Our NR IV comparison explains what the small study can and cannot support.

Product quality is a separate issue

FDA has described inappropriate food-grade NAD+ ingredients in IV preparations and reported reactions consistent with excessive endotoxins ². A comfortable infusion does not prove the preparation was made to appropriate standards, and a good-looking bag does not establish quality.

Ask for the pharmacy or facility that prepared the product. Find out who answers questions about ingredient suitability and testing. FDA approval and compounding are different concepts; a clinic should explain that distinction without presenting a registration number as product approval ³.

What should a clinic be able to explain?

A treatment plan should name the goal and describe how you will know whether continuing is worthwhile. Ask about the evidence for your goal, not just how many clients return. Repeat bookings can reflect many things and are not a controlled measure of benefit.

Confirm who is responsible for care during the appointment and what happens if you develop a reaction. A clinic should be able to explain monitoring, escalation and aftercare in plain language before treatment starts. Consider the response itself part of your decision.

Are home injections safer than IVs?

They avoid some aspects of an infusion visit but introduce other responsibilities: storage, prescription interpretation, injection teaching, sharps disposal and access to help. There is not enough comparative clinical evidence to declare one route universally safer or more effective.

The home-injection questions explain what must be taught for a prescription. Do not use an IV protocol to guide a home shot or attempt an IV at home. For side effects across routes, use the NAD+ safety guide.

Does a normal blood test prove long-term safety?

No. Tests are specific measurements at a specific time. A short study without a change in a laboratory measure cannot exclude uncommon reactions, future complications or risks in people unlike the participants. That is particularly relevant if a clinic recommends indefinite treatment.

Discuss your health conditions and medicines with the prescriber, and ask what uncertainty remains for you. Our IV evidence review and is NAD+ therapy worth it? help put the expected benefit alongside the time, expense and risks.

This page is educational. For severe symptoms during or after an infusion, seek urgent medical assessment rather than waiting for an online explanation.

How strong is the human safety evidence?

The NAD+-versus-NR pilot observed clients receiving four consecutive days of infusions and short follow-up ¹. Six NAD+ recipients and eight NR recipients are too few to estimate a rare complication rate. The study also does not represent every age, health condition, pharmacy preparation or clinic protocol.

Do not turn “no significant laboratory change” into “no risk.” Statistical nonsignificance can reflect a small sample, short observation or the fact that a test does not capture the outcome of concern. Conversely, a symptom report does not by itself identify a single cause. Proper assessment needs the product, timing, clinical setting and patient's circumstances.

Add-on ingredients deserve their own safety questions

The same scrutiny applies if glutathione is added to a wellness plan. In an August 2026 alert, FDA described reports involving at least 30 patients after IV glutathione alone or in combinations and identified dietary-supplement-grade source material as a concern ⁴. That alert is about injectable-product quality; it is not evidence that every glutathione product or every NAD+ clinic shares that problem.

Ask about each ingredient and preparation rather than assuming the clinic's NAD+ explanation covers the whole menu. The NAD+ and glutathione guide explains why oral supplement findings do not establish IV combination benefit.

Before, during and after the appointment

Before the appointment, share medicines, supplements and relevant health history with the prescriber. Ask whether anything about your situation changes the risk–benefit discussion. Resolve the intended goal and the full fee before committing to a package.

During treatment, report symptoms promptly rather than enduring them to complete a prepaid session. The treating professional needs to decide what they mean and whether treatment should stop. Ask in advance who makes that decision and what support is available if a more urgent assessment is needed.

Afterward, keep the clinic's contact and instructions available. If you experience a suspected adverse event, the product and pharmacy details can help the treating team investigate. FDA's MedWatch reporting system is also available for suspected problems; reporting does not itself prove causation.

A useful clinic conversation acknowledges what is uncertain and makes escalation clear. Confidence without specific answers is less useful than a candid explanation of the evidence and a workable care plan.